<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000045026"><TermName>CT-2103</TermName><TermDefinition><DefinitionText>A form of the anticancer drug paclitaxel combined with a protein called poliglumex that may have fewer side effects and work better than paclitaxel. It is being studied in the treatment of breast cancer, ovarian cancer, lung cancer, and other types of cancer. It belongs to the family of drugs called mitotic inhibitors. Also called paclitaxel poliglumex, paclitaxel polyglutamate,  and Xyotax.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><SpanishTermName>CT-2103</SpanishTermName><SpanishTermDefinition><DefinitionText>Tipo de paclitaxel, un medicamento contra el cáncer que se combina con una proteína llamada poliglumex que podría tener menos efectos secundarios y funcionar mejor que el paclitaxel. Está en estudio para el tratamiento del cáncer de mama (seno), cáncer de ovario, cáncer de pulmón y otros tipos de cáncer. Es un tipo de inhibidor mitótico. También se llama paclitaxel poliglumex, poliglutamato de paclitaxel,  y Xyotax.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateLastModified>2006-11-07</DateLastModified></GlossaryTerm>
